{"id":2567,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2017-05-17","marketCap":150.865,"name":"G1 Therapeutics Inc","phone":"19192139835","outstanding":51.84,"symbol":"GTHX","website":"https://www.g1therapeutics.com/","industry":"Biotechnology"},"price":3.00125,"year":2023,"month":12,"day":30,"weekday":"Saturday","title":"Financial Performance of G1 Therapeutics Inc","date":"2023-12-30","url":"/posts/2023/12/30/GTHX","content":[{"section":"Revenue","text":"G1 Therapeutics Inc has experienced consistent revenue growth over the past few years. In 2018, the company reported revenue of $2.9 million, which increased to $22.1 million in 2019, representing a year-over-year growth rate of 661%. This growth continued in 2020, with revenue reaching $31.1 million, a further increase of 40%. The strong revenue growth indicates the company's ability to attract and retain customers."},{"section":"Earnings","text":"While G1 Therapeutics Inc has not yet reported positive earnings, the company has been able to reduce its net losses over the past few years. In 2018, the company reported a net loss of $53.4 million, which decreased to $47.7 million in 2019. This trend continued in 2020, with a net loss of $38.8 million. The narrowing net losses suggest that the company is making progress towards profitability."},{"section":"Cash Flow","text":"G1 Therapeutics Inc has demonstrated positive operating cash flow in recent years. In 2018, the company generated $5.7 million in operating cash flow, which increased to $18.9 million in 2019, representing a growth rate of 232%. The positive cash flow indicates the company's ability to generate cash from its core operations. However, the company reported a decrease in operating cash flow in 2020, with a total of $15.6 million. It is important to note that the company's cash flow can fluctuate due to various factors, including investments in research and development."},{"section":"","text":""},{"section":"","text":""},{"section":"","text":""},{"section":"","text":""},{"section":"","text":""}],"tags":["CrossOver21","Long","Biotechnology"],"news":[{"category":"company","date":1702539180,"headline":"OPEN, SBSW and RDFN are among pre-market gainers","id":124512752,"image":"","symbol":"GTHX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3256749609"},{"category":"company","date":1702537740,"headline":"OPEM, SBSW and RDFN are among pre market gainers","id":124512753,"image":"","symbol":"GTHX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3256722400"},{"category":"company","date":1702526728,"headline":"Insider Sell Alert: Chief Medical Officer Rajesh Malik Offloads Shares of G1 Therapeutics Inc","id":124505426,"image":"https://media.zenfs.com/en/us.finance.gurufocus/4409c83c32547d73344be0888a168ede","symbol":"GTHX","publisher":"Yahoo","summary":"In a notable insider transaction, Chief Medical Officer Rajesh Malik has sold a significant number of shares in G1 Therapeutics Inc (NASDAQ:GTHX), a clinical-stage biopharmaceutical company.","url":"https://finance.yahoo.com/news/insider-sell-alert-chief-medical-040528682.html"},{"category":"company","date":1702295820,"headline":"GTHX, MRKR and CLIR among mid-day movers","id":124439674,"image":"","symbol":"GTHX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3251664322"},{"category":"company","date":1702294560,"headline":"12 Health Care Stocks Moving In Monday's Intraday Session","id":124438974,"image":"","symbol":"GTHX","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3251636486"},{"category":"company","date":1702281600,"headline":"G1 Therapeutics: Flying Low, Too Low","id":124434112,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1460014746/image_1460014746.jpg?io=getty-c-w1536","symbol":"GTHX","publisher":"SeekingAlpha","summary":"G1 Therapeutics' recent presentations on trilaciclib's potential benefits in breast cancer have sparked interest. Read why I'm bullish on GTHX stock.","url":"https://seekingalpha.com/article/4657127-g1-therapeutics-flying-low-too-low"},{"category":"company","date":1702030725,"headline":"G1 Therapeutics (NASDAQ:GTHX) adds US$67m to market cap in the past 7 days, though investors from five years ago are still down 90%","id":124396450,"image":"https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","symbol":"GTHX","publisher":"Yahoo","summary":"This month, we saw the G1 Therapeutics, Inc. ( NASDAQ:GTHX ) up an impressive 103%. But will that heal all the wounds...","url":"https://finance.yahoo.com/news/g1-therapeutics-nasdaq-gthx-adds-101845244.html"},{"category":"company","date":1701949020,"headline":"12 Health Care Stocks Moving In Thursday's Intraday Session","id":124367208,"image":"","symbol":"GTHX","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3246198919"},{"category":"company","date":1701892090,"headline":"Best Penny Stocks To Buy? 4 To Watch With Big News This Week","id":124340854,"image":"https://pennystocks.com/wp-content/uploads/2021/10/best-penny-stocks-to-watch-right-now-biotech-dna.jpg","symbol":"GTHX","publisher":"PennyStocks","summary":"Penny Stocks – How News Makes These Small Caps Soar or Plunge…","url":"https://pennystocks.com/featured/2023/12/06/best-penny-stocks-to-buy-4-to-watch-with-big-news-this-week/"},{"category":"company","date":1701837060,"headline":"Analysts Have Conflicting Sentiments on These Healthcare Companies: G1 Therapeutics (GTHX) and GoodRx Holdings (GDRX)","id":124340825,"image":"","symbol":"GTHX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3243807373"},{"category":"company","date":1701786360,"headline":"G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy","id":124323711,"image":"https://s.yimg.com/ny/api/res/1.2/H8BuQiE_BmgAYO8ijTNOeA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04NTI-/https://media.zenfs.com/en/globenewswire.com/9c8b716d1d490dc6c134902f61ef654c","symbol":"GTHX","publisher":"Yahoo","summary":"- Analyses of Data from the Randomized Phase 2 Metastatic Triple Negative Breast Cancer (mTNBC) Trial Indicate That Prior Use of Trilaciclib with Cytotoxic Chemotherapy is Highly Correlated to Improved Long-Term Survival with Subsequent Anticancer Therapies - - Improved Long-Term Survival Also Observed in Patients Who Received Prior Trilaciclib with Cytotoxic Therapy and Were Unable to Receive Subsequent Anticancer Therapy - - Data Presented at the 2023 San Antonio Breast Cancer Symposium (SABCS","url":"https://finance.yahoo.com/news/g1-therapeutics-presents-post-hoc-142600203.html"},{"category":"company","date":1701765120,"headline":"G1 Therapeutics presents post hoc analyses on trilaciclib with chemotherapy","id":124318524,"image":"","symbol":"GTHX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3242217024"},{"category":"company","date":1701684935,"headline":"G1 THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)","id":124276930,"image":"","symbol":"GTHX","publisher":"Finnhub","summary":"RESEARCH TRIANGLE PARK - G1 Therapeutics, Inc. , a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 4,700 shares of G1's common stock and 2,300...","url":"https://finnhub.io/api/news?id=d5ce1b39995bde43c884956de8713c8ea2ee278ad9c036df02c9749d4dd4d9d7"}]}